The use of pleuroperitoneal shunts in the management of persistent chylothorax in infants

Scott A. Engum, Frederick Rescorla, Karen W. West, L. R. Scherer, Jay L. Grosfeld

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background/Purpose: The development of chylothorax is a serious and often life-threatening clinical entity that may cause profound respiratory, nutritional, and immunologic complications and has become increasingly common in recent years. Optimal management of this problem has not been well defined because medical therapy has a significant failure rate. Surgical treatment of complicated chylothorax has become a mainstay of care. Methods: Over the last 36 months, seven infants had a pleuroperitoneal shunt placed for the management of refractory chylothorax. Ages ranged from 10 to 66 days with a weight between 1,000 to 4,850 g. Five of the seven infants were ventilator dependent. The etiologies were congenital in four and acquired in three with one related to a cardiothoracic procedure, one related to superior vena caval thrombosis, and one postoperative diaphragmatic hernia repair with superior vena caval thrombosis. Associated conditions included a left congenital diaphragmatic hernia, asplenia, isolated renal agenesis, bronchopulmonary dysplasia, and a patent ductus arteriosus. Each patient was unresponsive to thoracentesis, tube thoracostomy, and dietary manipulation with preoperative volume of chest tube output ranging from 50 to 162 cc/kg/d. The duration of preoperative therapy in congenital occurrences ranged from 10 to 46 days (average, 22 days). A Denver double-valved shunt system was used and catheters were implanted under general anesthesia. Manual pumping was required postoperatively on an hourly basis. Results: All seven patients had excellent results with the elimination of the chylothorax and resolution of symptoms. There were two complications. Shunt survival rate was six of seven (86%). Shunt removal ranged from 24 to 79 days (average, 44 days). Patient survival rate was five of seven (71%) with one infant dying of progressive pulmonary disease and one infant dying from viral sepsis; both had functioning shunts. One patient remains ventilator dependent secondary to chronic lung disease from prematurity. Conclusions: Pleuroperitoneal shunting is safe, simple, and an effective treatment of chylothorax in infants despite their size, age, or degree of prematurity.

Original languageEnglish
Pages (from-to)286-290
Number of pages5
JournalJournal of Pediatric Surgery
Volume34
Issue number2
DOIs
StatePublished - Feb 1999

Fingerprint

Chylothorax
Venae Cavae
Mechanical Ventilators
Lung Diseases
Thrombosis
Survival Rate
Thoracostomy
Chest Tubes
Bronchopulmonary Dysplasia
Diaphragmatic Hernia
Patent Ductus Arteriosus
Herniorrhaphy
Therapeutics
General Anesthesia
Sepsis
Chronic Disease
Catheters
Weights and Measures

Keywords

  • Chylothorax
  • Chylous effusion
  • Pleuroperitoneal shunt

ASJC Scopus subject areas

  • Surgery

Cite this

The use of pleuroperitoneal shunts in the management of persistent chylothorax in infants. / Engum, Scott A.; Rescorla, Frederick; West, Karen W.; Scherer, L. R.; Grosfeld, Jay L.

In: Journal of Pediatric Surgery, Vol. 34, No. 2, 02.1999, p. 286-290.

Research output: Contribution to journalArticle

Engum, Scott A. ; Rescorla, Frederick ; West, Karen W. ; Scherer, L. R. ; Grosfeld, Jay L. / The use of pleuroperitoneal shunts in the management of persistent chylothorax in infants. In: Journal of Pediatric Surgery. 1999 ; Vol. 34, No. 2. pp. 286-290.
@article{9dcfd30d9303450d8b390655e43097ec,
title = "The use of pleuroperitoneal shunts in the management of persistent chylothorax in infants",
abstract = "Background/Purpose: The development of chylothorax is a serious and often life-threatening clinical entity that may cause profound respiratory, nutritional, and immunologic complications and has become increasingly common in recent years. Optimal management of this problem has not been well defined because medical therapy has a significant failure rate. Surgical treatment of complicated chylothorax has become a mainstay of care. Methods: Over the last 36 months, seven infants had a pleuroperitoneal shunt placed for the management of refractory chylothorax. Ages ranged from 10 to 66 days with a weight between 1,000 to 4,850 g. Five of the seven infants were ventilator dependent. The etiologies were congenital in four and acquired in three with one related to a cardiothoracic procedure, one related to superior vena caval thrombosis, and one postoperative diaphragmatic hernia repair with superior vena caval thrombosis. Associated conditions included a left congenital diaphragmatic hernia, asplenia, isolated renal agenesis, bronchopulmonary dysplasia, and a patent ductus arteriosus. Each patient was unresponsive to thoracentesis, tube thoracostomy, and dietary manipulation with preoperative volume of chest tube output ranging from 50 to 162 cc/kg/d. The duration of preoperative therapy in congenital occurrences ranged from 10 to 46 days (average, 22 days). A Denver double-valved shunt system was used and catheters were implanted under general anesthesia. Manual pumping was required postoperatively on an hourly basis. Results: All seven patients had excellent results with the elimination of the chylothorax and resolution of symptoms. There were two complications. Shunt survival rate was six of seven (86{\%}). Shunt removal ranged from 24 to 79 days (average, 44 days). Patient survival rate was five of seven (71{\%}) with one infant dying of progressive pulmonary disease and one infant dying from viral sepsis; both had functioning shunts. One patient remains ventilator dependent secondary to chronic lung disease from prematurity. Conclusions: Pleuroperitoneal shunting is safe, simple, and an effective treatment of chylothorax in infants despite their size, age, or degree of prematurity.",
keywords = "Chylothorax, Chylous effusion, Pleuroperitoneal shunt",
author = "Engum, {Scott A.} and Frederick Rescorla and West, {Karen W.} and Scherer, {L. R.} and Grosfeld, {Jay L.}",
year = "1999",
month = "2",
doi = "10.1016/S0022-3468(99)90192-6",
language = "English",
volume = "34",
pages = "286--290",
journal = "Journal of Pediatric Surgery",
issn = "0022-3468",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - The use of pleuroperitoneal shunts in the management of persistent chylothorax in infants

AU - Engum, Scott A.

AU - Rescorla, Frederick

AU - West, Karen W.

AU - Scherer, L. R.

AU - Grosfeld, Jay L.

PY - 1999/2

Y1 - 1999/2

N2 - Background/Purpose: The development of chylothorax is a serious and often life-threatening clinical entity that may cause profound respiratory, nutritional, and immunologic complications and has become increasingly common in recent years. Optimal management of this problem has not been well defined because medical therapy has a significant failure rate. Surgical treatment of complicated chylothorax has become a mainstay of care. Methods: Over the last 36 months, seven infants had a pleuroperitoneal shunt placed for the management of refractory chylothorax. Ages ranged from 10 to 66 days with a weight between 1,000 to 4,850 g. Five of the seven infants were ventilator dependent. The etiologies were congenital in four and acquired in three with one related to a cardiothoracic procedure, one related to superior vena caval thrombosis, and one postoperative diaphragmatic hernia repair with superior vena caval thrombosis. Associated conditions included a left congenital diaphragmatic hernia, asplenia, isolated renal agenesis, bronchopulmonary dysplasia, and a patent ductus arteriosus. Each patient was unresponsive to thoracentesis, tube thoracostomy, and dietary manipulation with preoperative volume of chest tube output ranging from 50 to 162 cc/kg/d. The duration of preoperative therapy in congenital occurrences ranged from 10 to 46 days (average, 22 days). A Denver double-valved shunt system was used and catheters were implanted under general anesthesia. Manual pumping was required postoperatively on an hourly basis. Results: All seven patients had excellent results with the elimination of the chylothorax and resolution of symptoms. There were two complications. Shunt survival rate was six of seven (86%). Shunt removal ranged from 24 to 79 days (average, 44 days). Patient survival rate was five of seven (71%) with one infant dying of progressive pulmonary disease and one infant dying from viral sepsis; both had functioning shunts. One patient remains ventilator dependent secondary to chronic lung disease from prematurity. Conclusions: Pleuroperitoneal shunting is safe, simple, and an effective treatment of chylothorax in infants despite their size, age, or degree of prematurity.

AB - Background/Purpose: The development of chylothorax is a serious and often life-threatening clinical entity that may cause profound respiratory, nutritional, and immunologic complications and has become increasingly common in recent years. Optimal management of this problem has not been well defined because medical therapy has a significant failure rate. Surgical treatment of complicated chylothorax has become a mainstay of care. Methods: Over the last 36 months, seven infants had a pleuroperitoneal shunt placed for the management of refractory chylothorax. Ages ranged from 10 to 66 days with a weight between 1,000 to 4,850 g. Five of the seven infants were ventilator dependent. The etiologies were congenital in four and acquired in three with one related to a cardiothoracic procedure, one related to superior vena caval thrombosis, and one postoperative diaphragmatic hernia repair with superior vena caval thrombosis. Associated conditions included a left congenital diaphragmatic hernia, asplenia, isolated renal agenesis, bronchopulmonary dysplasia, and a patent ductus arteriosus. Each patient was unresponsive to thoracentesis, tube thoracostomy, and dietary manipulation with preoperative volume of chest tube output ranging from 50 to 162 cc/kg/d. The duration of preoperative therapy in congenital occurrences ranged from 10 to 46 days (average, 22 days). A Denver double-valved shunt system was used and catheters were implanted under general anesthesia. Manual pumping was required postoperatively on an hourly basis. Results: All seven patients had excellent results with the elimination of the chylothorax and resolution of symptoms. There were two complications. Shunt survival rate was six of seven (86%). Shunt removal ranged from 24 to 79 days (average, 44 days). Patient survival rate was five of seven (71%) with one infant dying of progressive pulmonary disease and one infant dying from viral sepsis; both had functioning shunts. One patient remains ventilator dependent secondary to chronic lung disease from prematurity. Conclusions: Pleuroperitoneal shunting is safe, simple, and an effective treatment of chylothorax in infants despite their size, age, or degree of prematurity.

KW - Chylothorax

KW - Chylous effusion

KW - Pleuroperitoneal shunt

UR - http://www.scopus.com/inward/record.url?scp=0032996764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032996764&partnerID=8YFLogxK

U2 - 10.1016/S0022-3468(99)90192-6

DO - 10.1016/S0022-3468(99)90192-6

M3 - Article

C2 - 10052806

AN - SCOPUS:0032996764

VL - 34

SP - 286

EP - 290

JO - Journal of Pediatric Surgery

JF - Journal of Pediatric Surgery

SN - 0022-3468

IS - 2

ER -